DK0914097T3 - Sammensætning og doseringsform omfattende opioid antagonist - Google Patents

Sammensætning og doseringsform omfattende opioid antagonist

Info

Publication number
DK0914097T3
DK0914097T3 DK97908764T DK97908764T DK0914097T3 DK 0914097 T3 DK0914097 T3 DK 0914097T3 DK 97908764 T DK97908764 T DK 97908764T DK 97908764 T DK97908764 T DK 97908764T DK 0914097 T3 DK0914097 T3 DK 0914097T3
Authority
DK
Denmark
Prior art keywords
composition
dosage form
opioid antagonist
matter
disclosed
Prior art date
Application number
DK97908764T
Other languages
English (en)
Inventor
Jerry D Childers
Glen E Barclay
Susan Rogriguez
Sonya Merrill
Anthony L Kuczynski
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Application granted granted Critical
Publication of DK0914097T3 publication Critical patent/DK0914097T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
DK97908764T 1996-03-12 1997-02-28 Sammensætning og doseringsform omfattende opioid antagonist DK0914097T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1329096P 1996-03-12 1996-03-12
PCT/US1997/003110 WO1997033566A2 (en) 1996-03-12 1997-02-28 Composition and dosage form comprising opioid antagonist

Publications (1)

Publication Number Publication Date
DK0914097T3 true DK0914097T3 (da) 2002-04-29

Family

ID=21759200

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97908764T DK0914097T3 (da) 1996-03-12 1997-02-28 Sammensætning og doseringsform omfattende opioid antagonist

Country Status (10)

Country Link
US (1) US5866164A (da)
EP (1) EP0914097B1 (da)
AT (1) ATE211906T1 (da)
AU (1) AU2059297A (da)
DE (1) DE69709646T2 (da)
DK (1) DK0914097T3 (da)
ES (1) ES2168610T3 (da)
HK (1) HK1019705A1 (da)
PT (1) PT914097E (da)
WO (1) WO1997033566A2 (da)

Families Citing this family (191)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103258A (en) * 1996-04-12 2000-08-15 Simon; David Lew Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics
DE19651551C2 (de) * 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
EP0880352B1 (de) * 1997-02-14 1999-11-17 Gödecke Aktiengesellschaft Stabilisierung von naloxonhydrochlorid
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
US6559158B1 (en) * 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
RS50070B (sr) 1997-12-22 2009-01-22 Euro-Celtique S.A., Oralni dozni oblik sa kombinacijom opijatnog agonista i antagonista
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
EP1041988A4 (en) * 1997-12-22 2002-03-13 Euro Celtique Sa METHOD FOR PREVENTING ABUSE OF OPIOID DOSES FORMS
IT1302682B1 (it) 1998-10-16 2000-09-29 Formenti Farmaceutici Spa Composizioni farmaceutiche orali contenenti buprenorfina
US20090297602A1 (en) * 1998-11-02 2009-12-03 Devane John G Modified Release Loxoprofen Compositions
US6835194B2 (en) * 1999-03-18 2004-12-28 Durect Corporation Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
US6541021B1 (en) * 1999-03-18 2003-04-01 Durect Corporation Devices and methods for pain management
EP1175206A1 (en) * 1999-05-13 2002-01-30 Unihart Corporation Pharmaceutical compositions comprising apocodeine and/or its derivatives
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
ATE526950T1 (de) * 1999-10-29 2011-10-15 Euro Celtique Sa Hydrocodon-formulierungen mit gesteuerter freisetzung
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
EP2517710B1 (en) * 2000-02-08 2015-03-25 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
US7074803B2 (en) * 2001-03-02 2006-07-11 Durect Corporation Opioid formulations
WO2001076602A1 (en) 2000-04-07 2001-10-18 Tap Pharmaceutical Products Inc. Apomorphine derivatives and methods for their use
AU2001274307A1 (en) * 2000-06-22 2002-01-02 Pharmasol Ltd Pharmaceutical compositions
EP2263658A1 (en) 2000-10-30 2010-12-22 Euro-Celtique S.A. Controlled release hydrocodone formulations
AU2002235129A1 (en) 2000-11-15 2002-05-27 Tap Pharmaceutical Products Inc. Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
CN1525851A (zh) 2001-05-11 2004-09-01 ������ҩ�����޹�˾ 抗滥用阿片样物质控释剂型
AU2002303718B2 (en) * 2001-05-11 2008-02-28 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
AU2002339378A1 (en) 2001-05-22 2002-12-03 Euro-Celtique Compartmentalized dosage form
AU2002314967B2 (en) * 2001-06-05 2007-09-20 University Of Chicago Use of methylnaltrexone to treat immune suppression
ATE419039T1 (de) * 2001-07-18 2009-01-15 Euro Celtique Sa Pharmazeutische kombinationen von oxycodon und naloxon
DE60232417D1 (de) 2001-08-06 2009-07-02 Euro Celtique Sa Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20030157168A1 (en) * 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
EP1429739A1 (en) 2001-09-21 2004-06-23 Egalet A/S Polymer release system
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
US20140271788A1 (en) 2013-03-15 2014-09-18 Monosol Rx, Llc Sublingual and buccal film compositions
MXPA04003597A (es) 2001-10-18 2004-07-30 Nektar Therapeutics Al Corp Conjugados polimericos de antagonistas opiaceos.
US8329217B2 (en) * 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
US20030185882A1 (en) * 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
US20030229111A1 (en) * 2002-03-14 2003-12-11 Benjamin Oshlack Naltrexone hydrochloride compositions
DK2425824T5 (da) 2002-04-05 2018-02-12 Mundipharma As Farmaceutisk præparat indeholdende oxycodon og naloxon
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
MXPA04012021A (es) * 2002-05-31 2005-08-16 Johnson & Johnson Formas de dosis y composiciones para la administracion osmotica de dosis variables de oxicodona.
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
AU2003283055A1 (en) * 2002-08-09 2004-02-25 Grunenthal Gmbh Opioid-receptor antagonists in transdermal systems having buprenorphine
AU2003272601B2 (en) * 2002-09-20 2009-05-07 Alpharma Pharmaceuticals, Llc Sustained-release opioid formulations and methods of use
EP2422772A3 (en) * 2002-09-20 2012-04-18 Alpharma, Inc. Sequestering subunit and related compositions and methods
DE10250088A1 (de) * 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20050186139A1 (en) * 2002-10-25 2005-08-25 Gruenenthal Gmbh Abuse-proofed dosage form
DE10250087A1 (de) * 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20050191244A1 (en) * 2002-10-25 2005-09-01 Gruenenthal Gmbh Abuse-resistant pharmaceutical dosage form
DE10250084A1 (de) * 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20040102476A1 (en) * 2002-11-25 2004-05-27 Chan Tai Wah High concentration formulations of opioids and opioid derivatives
US20070077301A1 (en) * 2002-12-23 2007-04-05 Meyer Glenn A Venlafaxine osmotic device formulation
US8293799B2 (en) * 2003-12-29 2012-10-23 Osmotica Keresleedelmo és Szolgáltató KFT Osmotic device containing a venlafaxine salt and a salt having an ion in common
EP1610767B1 (en) 2003-03-26 2011-01-19 Egalet A/S Morphine controlled release system
CA2521420A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist
US20040202717A1 (en) * 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
DK2368553T3 (da) 2003-04-08 2015-02-09 Progenics Pharm Inc Lægemiddelsammensætning der omfatter methylnaltrexon
WO2004091622A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
CN1784221B (zh) 2003-04-29 2010-07-07 奥雷西根治疗公司 影响体重减轻的组合物
CA2522529C (en) * 2003-04-30 2015-10-20 Purdue Pharma L.P. Tamper resistant transdermal dosage form
US8790689B2 (en) 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
DE102005005446A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004020220A1 (de) * 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE102004032051A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
US20070048228A1 (en) * 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
PL1842533T3 (pl) * 2003-08-06 2013-08-30 Gruenenthal Gmbh Postać aplikacyjna zabezpieczona przed nadużyciem
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
WO2005032555A2 (en) * 2003-09-25 2005-04-14 Euro-Celtique S.A. Pharmaceutical combinations of hydrocodone and naltrexone
AU2004275816A1 (en) * 2003-09-26 2005-04-07 Alza Corporation Controlled release formulations of opioid and nonopioid analgesics
ATE544447T1 (de) * 2003-09-26 2012-02-15 Alza Corp Arzneistoffcoating mit hohem wirkstoffanteil sowie methoden zu dessen herstellung
ATE504288T1 (de) * 2003-09-26 2011-04-15 Alza Corp Oros-push-stick für die kontrollierte abgabe von wirkstoffen
US20060182692A1 (en) * 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
PL1694363T3 (pl) * 2003-12-16 2014-07-31 Nektar Therapeutics Monodyspersyjne kompozycje PEGylowanego naloksolu
EP1604666A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
SI1765292T1 (en) 2004-06-12 2018-04-30 Collegium Pharmaceutical, Inc. Formulations of medicines to discourage abuse
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
PL1765303T5 (pl) * 2004-07-01 2023-05-22 Grünenthal GmbH Tabletka doustna zabezpieczona przed nadużywaniem
DE102004032103A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
WO2006002886A1 (de) * 2004-07-01 2006-01-12 Grünenthal GmbH Gegen missbrauch gesicherte, orale darreichungsform enthaltend (1r, 2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
US8541026B2 (en) * 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
AR053986A1 (es) 2004-12-03 2007-05-30 Osmotica Pharmaceutical Argent Dispositivo osmotico que contiene amantadina y una sal osmotica
MX2007008756A (es) * 2005-01-20 2007-09-27 Progenics Pharm Inc Uso de metilnaltrexona y compuestos relacionados para el tratamiento de disfuncion gastrointestinal postoperatoria.
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
CN101171010B (zh) 2005-03-07 2014-09-17 芝加哥大学 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途
AR057035A1 (es) * 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
US20080194611A1 (en) * 2005-06-03 2008-08-14 Alverdy John C Modulation of Cell Barrier Dysfunction
MX337422B (es) 2005-11-22 2016-03-04 Orexigen Therapeutics Inc Composiciones y metodos para incrementar la sencibilidad a la insulina.
EP1810678A1 (de) * 2006-01-19 2007-07-25 Holger Lars Hermann Verwendung einer Kombination von Morphin und Naloxon zur Drogensubstitution
US20090022798A1 (en) * 2007-07-20 2009-01-22 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
US20100172989A1 (en) * 2006-01-21 2010-07-08 Abbott Laboratories Abuse resistant melt extruded formulation having reduced alcohol interaction
US20090317355A1 (en) * 2006-01-21 2009-12-24 Abbott Gmbh & Co. Kg, Abuse resistant melt extruded formulation having reduced alcohol interaction
US8916195B2 (en) * 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR101486228B1 (ko) 2006-06-19 2015-01-26 알파마 파머슈티컬스 엘엘씨 약제학적 조성물
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
EP1897543A1 (en) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
JP2010506833A (ja) * 2006-10-11 2010-03-04 アルファーマ，インコーポレイテッド 医薬組成物
CA2674915C (en) * 2006-10-17 2015-06-30 Penick Corporation Process for preparing oxymorphone
US20080125592A1 (en) * 2006-10-17 2008-05-29 Penick Corporation Process for preparing oxymorphone, naltrexone, and buprenorphine
TWI609702B (zh) 2006-11-09 2018-01-01 歐瑞根治療有限公司 層狀醫藥調配物
KR20140088619A (ko) * 2006-11-09 2014-07-10 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
DE102007011485A1 (de) * 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
PL2137191T3 (pl) 2007-03-29 2016-12-30 Antagoniści obwodowego receptora opioidowego i ich zastosowania
EP2134718A2 (en) 2007-03-29 2009-12-23 Progenics Pharmaceuticals, Inc. Crystal forms of (r)-n-methylnaltrexone bromide and uses thereof
PT2139890E (pt) 2007-03-29 2014-09-03 Wyeth Llc Antagonistas do receptor opióide periférico e respectivas utilizações
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
WO2009032246A2 (en) 2007-09-03 2009-03-12 Nanotherapeutics, Inc. Particulate compositions for delivery of poorly soluble drugs
AU2014250614B2 (en) * 2007-09-04 2016-11-10 Alpharma Pharmaceuticals, Llc A multilayer pharmaceutical composition comprising an antagonist in a first layer and an agonist in a second layer
WO2009032270A2 (en) * 2007-09-04 2009-03-12 Alpharma, Inc. A multilayer pharmaceutical composition comprising an antagonist in a first layer and an agonist in a second layer
AU2015200313B2 (en) * 2007-12-17 2016-12-01 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
AU2008343267A1 (en) * 2007-12-17 2009-07-09 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
CA2709905A1 (en) * 2007-12-17 2009-06-25 Alfred Liang Abuse-resistant oxycodone composition
WO2009088673A2 (en) * 2007-12-17 2009-07-16 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
EP2219612A4 (en) 2007-12-17 2013-10-30 Paladin Labs Inc CONTROLLED RELEASE FORMULATION AVOIDING IMPROPER USES
CA2709903A1 (en) * 2007-12-17 2009-06-25 Alpharma Pharmaceuticals, Llc Oral opioid compositions with opioid antagonist
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
BRPI0906467C1 (pt) * 2008-01-25 2021-05-25 Gruenenthal Gmbh forma de dosagem farmacêutica com formato exterior modificado resistente à ruptura e com liberação controlada
US20090246276A1 (en) 2008-01-28 2009-10-01 Graham Jackson Pharmaceutical Compositions
US9226907B2 (en) 2008-02-01 2016-01-05 Abbvie Inc. Extended release hydrocodone acetaminophen and related methods and uses thereof
AU2008349873B2 (en) 2008-02-06 2014-02-13 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone
AU2009225434B2 (en) * 2008-03-21 2014-05-22 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
WO2009135846A1 (en) * 2008-05-05 2009-11-12 Euro-Celtique S.A. Opioid composition for treating skin lesions
KR101690094B1 (ko) 2008-05-09 2016-12-27 그뤼넨탈 게엠베하 분무 응결 단계의 사용하에 중간 분말 제형 및 최종 고체 제형을 제조하는 방법
JP2011521973A (ja) 2008-05-30 2011-07-28 オレキシジェン・セラピューティクス・インコーポレーテッド 内臓脂肪の状態を処置するための方法
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
CN105456267A (zh) * 2008-07-07 2016-04-06 欧洲凯尔特公司 阿片类拮抗剂治疗尿潴留的用途
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
PE20190391A1 (es) 2008-10-30 2019-03-13 Gruenenthal Chemie Formas de dosificacion del tapentadol novedosas y potentes
EP2367541B1 (en) 2008-12-16 2014-07-16 Paladin Labs Inc. Misuse preventative, controlled release formulation
WO2010089132A1 (en) 2009-02-06 2010-08-12 Egalet A/S Immediate release composition resistant to abuse by intake of alcohol
WO2010103039A1 (en) 2009-03-10 2010-09-16 Euro-Celtique S.A. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
CA2757979A1 (en) * 2009-04-09 2010-10-14 Alkermes Pharma Ireland Limited Controlled-release clozapine compositions
EP2445487A2 (en) 2009-06-24 2012-05-02 Egalet Ltd. Controlled release formulations
PE20121067A1 (es) 2009-07-22 2012-09-05 Gruenenthal Chemie Forma de dosificacion de liberacion controlada extruida por fusion en caliente
WO2011009604A1 (en) 2009-07-22 2011-01-27 Grünenthal GmbH Oxidation-stabilized tamper-resistant dosage form
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
KR101841442B1 (ko) * 2010-01-11 2018-03-23 오렉시젠 세러퓨틱스 인크. 주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법
ES2606227T3 (es) * 2010-02-03 2017-03-23 Grünenthal GmbH Preparación de una composición farmacéutica en polvo mediante una extrusora
IT1398930B1 (it) * 2010-03-24 2013-03-28 Molteni & C Formulazioni farmaceutiche bistrato contenenti agonisti ed antagonisti oppioidi.
AR082167A1 (es) 2010-07-14 2012-11-14 Gruenenthal Gmbh Formas de dosificacion gastrorretentivas
WO2012028319A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising inorganic salt
CA2808541C (en) 2010-09-02 2019-01-08 Gruenenthal Gmbh Tamper resistant dosage form comprising an anionic polymer
EP2446882B8 (de) 2010-10-28 2014-02-12 Acino Pharma AG Arzneimittel mit dem Wirkstoff Hydromorphon mit verbesserter Lagerstabilität
US20120310140A1 (en) 2010-12-01 2012-12-06 Spinal Modulation, Inc. Directed delivery of agents to neural anatomy
SG191288A1 (en) 2010-12-22 2013-07-31 Purdue Pharma Lp Encased tamper resistant controlled release dosage forms
JP5638151B2 (ja) 2010-12-23 2014-12-10 パーデュー、ファーマ、リミテッド、パートナーシップ 不正加工抵抗性の（ｔａｍｐｅｒｒｅｓｉｓｔａｎｔ）固形経口剤形
KR20140053158A (ko) 2011-07-29 2014-05-07 그뤼넨탈 게엠베하 즉시 약물 방출을 제공하는 탬퍼-저항성 정제
AR087360A1 (es) 2011-07-29 2014-03-19 Gruenenthal Gmbh Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato
PL2915525T3 (pl) 2011-09-19 2022-01-17 Orexo Ab Tabletki podjęzykowe niepodatne na nadużywanie zawierające buprenorfinę i nalokson
US20130129826A1 (en) 2011-11-17 2013-05-23 Gruenenthal Gmbh Tamper-resistant oral pharmaceutical dosage form comprising opioid antagonist and/or aversive agent, polyalkylene oxide and anionic polymer
CA2853764C (en) * 2011-11-22 2017-05-16 Watson Pharmaceuticals, Inc. Immediate release abuse deterrent tablet
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
CA2864949A1 (en) 2012-02-28 2013-09-06 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
JP6282261B2 (ja) 2012-04-18 2018-02-21 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 不正使用防止および過量放出防止医薬剤形
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CA2875056C (en) 2012-06-06 2024-03-26 Orexigen Therapeutics, Inc. Methods of treating overweight and obesity
JP2015521988A (ja) 2012-07-06 2015-08-03 イガレット・リミテッド 制御放出用乱用防止性医薬組成物
US9149533B2 (en) 2013-02-05 2015-10-06 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9517208B2 (en) 2013-03-15 2016-12-13 Purdue Pharma L.P. Abuse-deterrent dosage forms
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
CA2913209A1 (en) 2013-05-29 2014-12-04 Grunenthal Gmbh Tamper resistant dosage form with bimodal release profile
EP3003279A1 (en) 2013-05-29 2016-04-13 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
JP2016520653A (ja) 2013-06-05 2016-07-14 シンクロニューロン インコーポレイテッド アカンプロサート製剤、それを用いる方法、およびそれを含む合剤
AU2014289187B2 (en) 2013-07-12 2019-07-11 Grunenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
AU2014295042B2 (en) 2013-07-23 2017-03-30 Mundipharma Pty Limited A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
MX371372B (es) 2013-11-26 2020-01-28 Gruenenthal Gmbh Preparacion de una composicion farmaceutica en polvo por medio de criomolienda.
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CA2947786A1 (en) 2014-05-12 2015-11-19 Grunenthal Gmbh Tamper resistant immediate release capsule formulation comprising tapentadol
WO2015181059A1 (en) 2014-05-26 2015-12-03 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
JP6371463B2 (ja) 2014-07-17 2018-08-08 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 即時放出性乱用抑止性液体充填剤形
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
EP3209282A4 (en) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
JP2018517676A (ja) 2015-04-24 2018-07-05 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 即時放出および溶媒抽出に対する耐性を有する改変防止製剤
WO2017042325A1 (en) 2015-09-10 2017-03-16 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US20170312226A1 (en) * 2016-04-28 2017-11-02 Ascent Pharmaceuticals, Inc. Pharmaceutical dosage forms
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4036228A (en) * 1975-09-11 1977-07-19 Alza Corporation Osmotic dispenser with gas generating means
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4111201A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for delivering selected beneficial agents having varying degrees of solubility
US4111202A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
JPS59500418A (ja) * 1982-03-16 1984-03-15 ザ　ロツクフエラ−　ユニバ−シテイ 胃腸能動作用障害を回復する方法
US4519801A (en) * 1982-07-12 1985-05-28 Alza Corporation Osmotic device with wall comprising cellulose ether and permeability enhancer
US4576604A (en) * 1983-03-04 1986-03-18 Alza Corporation Osmotic system with instant drug availability
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
GB8521350D0 (en) * 1985-08-28 1985-10-02 Euro Celtique Sa Analgesic composition
US4764378A (en) * 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
GB8626098D0 (en) * 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
GB8728294D0 (en) * 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
US5236714A (en) * 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
US5021053A (en) * 1989-07-14 1991-06-04 Alza Corporation Oral osmotic device with hydrogel driving member
US5151093A (en) * 1990-10-29 1992-09-29 Alza Corporation Osmotically driven syringe with programmable agent delivery
US5208037A (en) * 1991-04-22 1993-05-04 Alza Corporation Dosage forms comprising polymers comprising different molecular weights
US5198229A (en) * 1991-06-05 1993-03-30 Alza Corporation Self-retaining gastrointestinal delivery device
US5460826A (en) * 1994-06-27 1995-10-24 Alza Corporation Morphine therapy
US5529787A (en) * 1994-07-07 1996-06-25 Alza Corporation Hydromorphone therapy

Also Published As

Publication number Publication date
PT914097E (pt) 2002-06-28
US5866164A (en) 1999-02-02
ATE211906T1 (de) 2002-02-15
ES2168610T3 (es) 2002-06-16
EP0914097A2 (en) 1999-05-12
EP0914097B1 (en) 2002-01-16
WO1997033566A2 (en) 1997-09-18
HK1019705A1 (en) 2000-02-25
DE69709646D1 (de) 2002-02-21
DE69709646T2 (de) 2002-08-14
WO1997033566A3 (en) 1997-11-06
AU2059297A (en) 1997-10-01

Similar Documents

Publication Publication Date Title
DK0914097T3 (da) Sammensætning og doseringsform omfattende opioid antagonist
FI965203A0 (fi) Morfiinia, polypyrrolidonia ja polyalkyleenioksidia sisältävä koostumus
EE9800173A (et) Gonadotropiini riliisinghormooni antagonistid
FI963040A0 (fi) Inhibitorer av poly(ADP-ribos)syntetas och anvaendning daerav foer att foerhindra NMDA-nervfoergiftning
LU90987I2 (fr) Copaxone et ses dérivés pharmaceutiquement acceptables
SK86699A3 (en) Nitrogen containing heteroaromatics as factor xa inhibitors
DK1041987T3 (da) Oral farmaceutisk doseringsform omfattende en kombination af en opioid-agonist og naltrexon
AU3110999A (en) Disubstituted pyrazolines and triazolines as factor xa inhibitors
PL350729A1 (en) Pharmaceutical composition containing proton pump inhibitors
ATE252885T1 (de) Plan zur verabreichung von h+, k+-atpase inhibitoren
DE10084671T1 (de) Pharmazeutische Zusammensetzungen
NZ335994A (en) Sevoflurane compositions and methods for inhibiting their degradation in the presence of a lewis acid
IT1287174B1 (it) Diaril-ciclometilenpirazoli farmacologicamente attivi,procedimento per prepararli e composizioni farmaceutiche che li contengono
DE69917663D1 (de) 2-methyl-thieno-benzodiazepin-formulierung
TR200001288T2 (tr) Östrojen yoksunluğu sendromunun tedavisinde faydalı 2-arilbenzo (b) tiyofenler.
DK1200139T3 (da) Fikseringsanordning
AU4594200A (en) Pharmaceutical combination of neurokinin receptor antagonist and proton pump inhibitor
NO20010647L (no) Dieseldrivstoff-blanding
ES2159260B1 (es) Nueva composicion de metanosulfonato de paroxetina
CO5251423A1 (es) Tratamiento de endometriosis o infertilidad, o mejora de la fertilidad
MY133169A (en) Substituted heterocyclic benzocycloalkenes and the use thereof as substances having an analgesic effect
WO2000034295A3 (en) Acylated benzylmaltosides as inhibitors of smooth muscle cell proliferation
ATE227571T1 (de) Thrombin inhibitoren
BR9902081A (pt) Combinação de dofetilida e um bloqueador dos canais de cálcio
FI964663A0 (fi) Farmaceutisk analgetisk komposition foer lokal administrering